Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EBITDA (2016 - 2025)

Historic EBITDA for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to -$22.5 million.

  • Seres Therapeutics' EBITDA fell 12531.88% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.2 million, marking a year-over-year decrease of 25419.43%. This contributed to the annual value of $136000.0 for FY2024, which is 10011.96% up from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' EBITDA is -$22.5 million, which was down 12531.88% from -$24.9 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' EBITDA registered a high of $88.8 million during Q3 2024, and its lowest value of -$71.2 million during Q1 2023.
  • Over the past 5 years, Seres Therapeutics' median EBITDA value was -$40.1 million (recorded in 2024), while the average stood at -$26.5 million.
  • As far as peak fluctuations go, Seres Therapeutics' EBITDA surged by 32529.48% in 2021, and later crashed by 18775.53% in 2022.
  • Over the past 5 years, Seres Therapeutics' EBITDA (Quarter) stood at -$50.1 million in 2021, then plummeted by 37.18% to -$68.7 million in 2022, then surged by 39.95% to -$41.2 million in 2023, then soared by 62.09% to -$15.6 million in 2024, then plummeted by 43.74% to -$22.5 million in 2025.
  • Its EBITDA was -$22.5 million in Q3 2025, compared to -$24.9 million in Q2 2025 and -$27.2 million in Q1 2025.